LUCÍA
GALÁN DÁVILA
Profesora asociada de Ciencias de la Salud
Publications (56) Publications de LUCÍA GALÁN DÁVILA
2024
-
Description of clinical and genetic features of 122 patients included in the Spanish Pompe registry
Neuromuscular Disorders, Vol. 34, pp. 1-8
2023
-
Factors associated with the severity of COVID-19 outcomes in people with neuromuscular diseases: Data from the International Neuromuscular COVID-19 Registry
European Journal of Neurology, Vol. 30, Núm. 2, pp. 399-412
-
Hereditary transthyretin amyloidosis caused by p.Ser43Asn variant. A new endemic variant in Ecuador
Revista Espanola de Cardiologia, Vol. 76, Núm. 7, pp. 564-566
-
Impact of Vutrisiran on Quality of Life and Physical Function in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy
Neurology and Therapy, Vol. 12, Núm. 5, pp. 1759-1775
-
Phenotype and clinical outcomes of Glu89Lys hereditary transthyretin amyloidosis: a new endemic variant in Spain
Amyloid, Vol. 30, Núm. 2, pp. 199-207
-
Red flags in patients with hereditary transthyretin amyloidosis at diagnosis in a non-endemic area of Spain
Neurologia, Vol. 38, Núm. 2, pp. 87-92
2022
-
Case Report: Novel STIM1 Gain-of-Function Mutation in a Patient With TAM/STRMK and Immunological Involvement
Frontiers in Immunology, Vol. 13
-
Cell therapy as a treatment strategy in amyotrophic lateral sclerosis
Neurology Perspectives, Vol. 2, pp. S69-S73
-
Clinical, histological, and genetic features of 25 patients with autosomal dominant progressive external ophthalmoplegia (Ad-PEO)/PEO-plus due to TWNK mutations
Journal of Clinical Medicine, Vol. 11, Núm. 1
2021
-
Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis: A Phase 2 Randomized Control Trial
Neurology, Vol. 96, Núm. 6, pp. E853-E865
-
Estimating the annual economic burden for the management of patients with transthyretin amyloid polyneuropathy in Spain
Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 21, Núm. 5, pp. 967-973
2020
-
Clinical and therapeutic features of myasthenia gravis in adults based on age at onset
Neurology, Vol. 94, Núm. 11, pp. e1171-e1180
-
Nivolumab: An «Immune storm» in a patient with history of myasthenia gravis
Neurologia
2019
-
Assessment of patients with hereditary transthyretin amyloidosis–understanding the impact of management and disease progression
Amyloid, Vol. 26, Núm. 3, pp. 103-111
-
Collagen XIX alpha 1 improves prognosis in amyotrophic lateral sclerosis
Aging and Disease, Vol. 10, Núm. 2, pp. 278-292
-
Early diagnosis of ATTR amyloidosis through targeted follow-up of identified carriers of TTR gene mutations*
Amyloid, Vol. 26, Núm. 1, pp. 3-9
-
Inhibition impairment in frontotemporal dementia, amyotrophic lateral sclerosis, and Alzheimer’s disease: clinical assessment and metabolic correlates
Brain Imaging and Behavior, Vol. 13, Núm. 3, pp. 651-659
-
Notch signalling in the hippocampus of patients with motor neuron disease
Frontiers in Neuroscience, Vol. 13, Núm. APR
2018
-
Analysis of known amyotrophic lateral sclerosis and frontotemporal dementia genes reveals a substantial genetic burden in patients manifesting both diseases not carrying the C9orf72 expansion mutation
Journal of Neurology, Neurosurgery and Psychiatry, Vol. 89, Núm. 2, pp. 162-168
-
Histological changes in the rat brain and spinal cord following prolonged intracerebroventricular infusion of cerebrospinal fluid from amyotrophic lateral sclerosis patients are similar to those caused by the disease
Neurologia, Vol. 33, Núm. 4, pp. 211-223